

JAIPURIA INSTITUTE OF MANAGEMENT, NOIDA

PGDM / PGDM (M) / PGDM (SM)

FIRST TRIMESTER (Batch 2023-25)

END TERM EXAMINATION, OCTOBER 2023

| Course Name | Accounting for Business | Course Code | 20201 |
|-------------|-------------------------|-------------|-------|
| Max. Time | 2 Hours | Max. Marks | 40 MM |

INSTRUCTIONS:

- a. It's an open book exam
- b. All questions are compulsory
- c. Marks for each question are given in the parenthesis
- d. Exchange or sharing of text book (Narayanaswamy) is strictly prohibited

Qs 1 (6 + 4 = 10)

(CLO 1 and BT Level II and III)

- (a) Dharm & Company has furnished following transactions for the month of September 2023. Show the effect of these transactions on the accounting equation:
- i. Started business by investing Rs.10,00,000 as follows: Rs.90,000 in cash; Rs.195,000 in furniture; Rs.320,000 in machinery; and balance in office building.
- ii. Received an order worth Rs.60,000 from a customer. Received an advance of Rs.10,000 against this order.
- iii. Purchased raw material from Thukral Brothers at Rs.30,000 to fulfill the order mentioned in (ii) above.
- iv. Machine work on the raw material was carried out by spending Rs. 6,000 and some other finishing was done at Rs.4,000.
- v. Rs. 5,000 as gifts were given away to the staff on the occasion of wedding of the owner's son.
- vi. Finished goods supplied to the customer as stated in (ii) above and received the amount due.
- (b) Information on accounting policies is listed below. Identify which accounting concept/ principle / convention is applied in formulating each of the accounting policy (write in the answer sheet only).

| S.No. | Accounting Policy | Accounting Concept/ Principle / Convention |
|-------|---|--|
| i | Revenue from the sale of goods is recognized only when the management is reasonably certain that the payment is realizable/will be received from the customer | |
| ii | Training expenses are recognized as expense in the accounting period in which these are incurred | |
| iii | Government grant receivable from the Government is not recognized in the books until the Government approval is received | |
| iv | Revenue from goods sold on credit is recorded when the customer accepts the goods even though cash payment has not been received | |

| V | Expenditure on research is recognized as expense in the period in which the expenditure is incurred | |
|------|--|--|
| vi | Personal expenses of the owner will not be treated as business expenses | |
| vii | Expenditure on repairs and maintenance should be recognized as expense in the profit and loss statement | |
| viii | Inventories are valued in the books of accounts at the cost or realizable value (market value), whichever is lower | |

Qs 2 (7 + 1 = 8)

(CLO 2 and BT Level III and V)

Mr. Vinod Kumar owns a soap manufacturing firm and wants to know various profit levels from the given financial information for the year 2022-23.

| Opening inventory of work in process (WIP) | Rs 10,25,000 |
|--|--------------|
| Opening inventory of finished goods | Rs 46,48,500 |
| Raw material consumed | Rs 13,18,000 |
| Labor cost (wages) | Rs 7,20,000 |
| Factory/manufacturing expenses | Rs 10,15,000 |
| Operating expenses (includes depreciation and amortization of Rs 3,27,500) | Rs 14,66,200 |
| Closing inventory of work in process | Rs 8,10,000 |
| Closing inventory of finished goods | Rs 36,12,800 |
| Revenue from sales | Rs 65,12,400 |

- (a) Construct a functional profit & loss statement and estimate gross profit, EBITDA, and EBIT.
- (b) He has set a target of 15% operating profit margin. Evaluate the firm's performance against this target.

Qs 3. (3+3+3+3=12)

(CLO 3 and BT Level V)

The financial ratios for the top three pharmaceutical companies are provided below:

| Name of Companies | Financial Ratios of Pharmaceutical Companies | Mar 2023 | Mar 2022 | Mar 2021 |
|-------------------------------|--|--|---|--|
| Cipla | - Current Ratio | 3.84 | 3.70 | 2.90 |
| Dr Reddys Laboratories | | 2.00 | 1.47 | 1.76 |
| Sun Pharmaceutical Industries | | 1.95 | 1.30 | 1.48 |
| Cipla | Quick Ratio | 2.74 | 2.61 | 1.89 |
| Dr Reddys Laboratories | | 1.33 | 2.22 | 2.07 |
| Sun Pharmaceutical Industries | | . 1.43 | 0.97 | 1.54 |
| | | | | |
| Cipla | Debt Equity Ratio | | | |
| Dr Reddys Laboratories | | | 0.12 | 0.07 |
| Sun Pharmaceutical Industries | | 0.32 | 0.20 | 0.26 |
| | Cipla Dr Reddys Laboratories Sun Pharmaceutical Industries Cipla Dr Reddys Laboratories Sun Pharmaceutical Industries Cipla Dr Reddys Laboratories Cipla Dr Reddys Laboratories Sun Pharmaceutical Industries | Name of Companies Cipla Dr Reddys Laboratories Sun Pharmaceutical Industries Cipla Dr Reddys Laboratories Sun Pharmaceutical Industries Quick Ratio Cipla Dr Reddys Laboratories Sun Pharmaceutical Industries Cipla Dr Reddys Laboratories Sun Pharmaceutical Industries Debt Equity Ratio | Name of Companiesof Pharmaceutical CompaniesMar 2023Cipla3.84Dr Reddys Laboratories2.00Sun Pharmaceutical IndustriesCurrent RatioCipla2.74Dr Reddys LaboratoriesQuick RatioSun Pharmaceutical Industries1.43CiplaDr Reddys LaboratoriesSun Pharmaceutical Sun PharmaceuticalDebt Equity RatioDebt Equity Ratio0.32 | Name of Companies of Pharmaceutical Companies Mar 2023 Mar 2022 Cipla 3.84 3.70 Dr Reddys Laboratories 2.00 1.47 Sun Pharmaceutical Industries 1.95 1.30 Cipla 2.74 2.61 Dr Reddys Laboratories Quick Ratio 1.33 2.22 Sun Pharmaceutical Industries Quick Ratio 1.43 0.97 Cipla Dr Reddys Laboratories Debt Equity Ratio 0.32 0.20 Sun Pharmaceutical Debt Equity Ratio 0.32 0.20 |

| 1 | Cipla | the expension the law mag | 135.21 | 132.68 | 75.34 |
|----------|--|----------------------------|--------|--------|-------|
| 2 | Dr Reddys Laboratories | Interest Coverage Ratio | 229.76 | 59.52 | 66.44 |
| 3 | Sun Pharmaceutical Industries | | 10.91 | 6.48 | 9.73 |
| | | | | | |
| 1 | Cipla | Inventory Turnover Ratio | 4.82 | 4.09 | 4.5 |
| 2 | Dr Reddys Laboratories | | 5.57 | 4.3 | 4.73 |
| 3 | Sun Pharmaceutical Industries | | 5.22 | 4.58 | 4.04 |
| 1 | Cipla | | 6.54 | 5.26 | 4.22 |
| 2 | Dr Reddys Laboratories | Receivable Turnover Ratio | 3.67 | 3.19 | 3.06 |
| 3 | Sun Pharmaceutical Industries | | 3.66 | 2.94 | 2.04 |
| | | | 0.05 | 0.50 | 0.74 |
| 1 | Cipla | | 0.65 | 0.59 | 0.71 |
| 2 | Dr Reddys Laboratories | Total Assets | 0.94 | 0.78 | 0.84 |
| 3 | Sun Pharmaceutical Industries | Turnover Ratio | 0.76 | 0.63 | 0.41 |
| 1 | Cipla | | 20.24 | 22.2 | 22.7 |
| | Dr Reddys | Gross Profit Margin (%) | 19.4 | 12.35 | 17.2 |
| 3 | Laboratories Sun Pharmaceutical Industries | | 23.4 | 9.99 | 18.3 |
| 1 | Cipla | | 15.91 | 22.59 | 17.7 |
| 2 | Dr Reddys Laboratories | Net Profit Margin (%) | 15.4 | 11.26 | 16.3 |
| 3 | Sun Pharmaceutical Industries | | 8.12 | -0.64 | 16.7 |
| <u> </u> | madaned | | | | |
| 1 | Cipla | | 14.82 | 15.87 | 17.0 |
| 2 | Dr Reddys Laboratories | Return On | 18.96 | 11.02 | 17.0 |
| 3 | Sun Pharmaceutical Industries | Investment (%) | 16.43 | 8.53 | 7.9 |
| 4 | Cipla | | 10.21 | 13.15 | 12. |
| 1 | Cipla Dr Reddys | - | | | |
| 2 | Laboratories | Return On Equity (%) | 12.76 | 8.85 | 12.8 |
| 3 | Sun Pharmaceutical Industries | | 7.11 | -0.4 | 8.5 |
| 1 | Cipla | | 31.15 | 36.67 | 30.6 |
| | Dr Reddys | Basic EPS (Rs.) | 157.37 | 97.85 | 131.8 |
| 3 | Laboratories Sun Pharmaceutical Industries | Dasic LF3 (Ns.) | 7 | -0.4 | 8.9 |

In the light of financial ratios above, interpret the following ratios of these Pharma Companies:

Short-term liquidity, Activity ratios, Solvency and Profitability

Provide the evaluation in the light of industry standards of Pharmaceutical Sector of India as below:

| Current ratio | 2.2: 1 |
|---|--------|
| 2. Inventory turnover (times) | 3.8 |
| 3. Average Collection period (days) | 19 |
| 4. Total debt/shareholders' equity (percentage) | 45 |
| 5. Interest coverage ratio (times) | 100 |
| 6. Assets turnover (times) | 1.35 |
| 7. Profit after tax/ Sales (percentage) | 11.9 |
| 8. Return on equity (percentage) | 10.9 |
| | |

Qs 4 (7 + 3 = 10)

(CLO 3 and BT Level IV and V)

You are a financial consultant and have been appointed by your client to evaluate the performance of two companies based on their cash flow statements. Below are **cash flows from operating activities** of the two firms for the year ended 31st March, 2023:

| Particulars | Aksara Ltd. (Rs. in lakhs) | Dorathan Ltd. (Rs. in lakhs) |
|---|-------------------------------|---------------------------------|
| Net Profit before tax | 106.28 | 129.45 |
| Adjustments for non-operating and non-cash | | |
| expenses: | | |
| Amortization of intangible assets | 7.27 | 8.94 |
| Interest on borrowed funds | 2.62 | 5.68 |
| Depreciation | 16.94 | 14.38 |
| Loss on sale of PPE | 1.25 | 1.39 |
| Rental income | (0.96) | - |
| Interest income | (12.41) | (5.94) |
| Other non-operating income | | (1.62) |
| Gain from sale of investments | (6.81) | (0.69) |
| Operating income before working capital changes | 114.18 | 151.59 |
| Adjustments for changes in working capital: | | |
| Increase in inventory | (5.45) | (2.29) |
| Increase in trade receivables | (9.89) | (0.77) |
| Decrease in other current assets | 0.80 | 2.01 |
| Increase in short-terms loans | 1.72 | 29.91 |
| Decrease in trade payables | (5.87) | (1.20) |
| Increase in other current liabilities | 0.81 | 9.48 |
| Cash generated from operations | 96.3 | 188.73 |
| Taxes paid | (17.91) | (45.06) |
| Net cash generated from operating activities | 78.39 | 143.67 |

Additional Information:

The net sales of Aksara Ltd. and Dorathan Ltd. are Rs. 723 lakhs and Rs. 984 lakhs, respectively. The current liabilities of Aksara Ltd. and Dorathan Ltd. are Rs. 46.5 lakhs and Rs. 124.47 lakhs, respectively.

As a financial consultant, you are required to:

- a) Examine the relevant cash flow ratios of both the companies and recommend which company is in a better position to run its business and meets its obligations with its current cash flows, without disruption of its activities. Use all relevant information.
- b) Your client wishes to know why the net cash from operating activities of Aksara Ltd is 83.27% lower than that of Dorathan Ltd. despite the fact that the net profit before tax for Aksara Ltd. was only 21.8% lower than that of Dorathan. Analyze the reasons for the same.